Adjuvant therapy for renal cell carcinoma: Past, present, and future

Oncologist

Volumn 19, Issue 8, 2014, Pages 851-859

  Pal, Sumanta K ^a   Haas, Naomi B ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvant; ASSURE; EVEREST; PROTECT; Renal cell carcinoma; S TRAC; SORCE

Indexed keywords

AGS 003; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AXITINIB; BEVACIZUMAB; DENDRITIC CELL VACCINE; DENDRITIC CELL VACCINE AGS 003; EVEROLIMUS; FLUOROURACIL; GIRENTUXIMAB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MPDL 3280A; MULTIPEPTIDE VACCINE IMA901; NIVOLUMAB; PAZOPANIB; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN; METHYLNITRONITROSOGUANIDINE; MTOR PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; DISEASE FREE SURVIVAL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; META ANALYSIS (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; GENETICS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; METHYLNITRONITROSOGUANIDINE; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905505196     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0105     Document Type: Article

References (69)

1. Pal SK, Williams S, Josephson DY et al. Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 2012; 11: 526-537.
2. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011; 378: 1931-1939.
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
5. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
6. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
7. Hu CY, Mohtat D, Yu Y et al. High-resolution methylome analysis of renal cell carcinoma and identification of aberrant epigenetic changes in gene bodies. J Clin Oncol 2011; 29(suppl): e15000a.
8. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
9. Ward HW. Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. BMJ 1973; 1: 13-14.
10. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 1996; 14: 2000-2011.
11. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816.
12. Colleoni M, Giobbie-Hurder A, Regan MMet al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29: 1117-1124.
13. Valero V, Forbes J, Pegram MD et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 2011; 29: 149-156.
14. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
15. Motzer RJ, Bacik J, Murphy BA et al. Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
16. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696.
17. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659.
18. Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J Clin Oncol 2001; 19: 425-431.
19. MessingEM, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214-1222.
20. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with highrisk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol 2003; 21: 3133-3140.
21. Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial. Cancer 2007; 110: 2468-2477.
22. Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): An open-label randomised trial. Lancet 2010; 375: 641-648.
23. Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843-846.
24. NCT00053807. Interleukin-2, interferon alfa, and fluorouracil compared with observation in treating patients who have undergone surgery for kidney cancer. Available at http: //www. clinicaltrials. gov/show/NCT00053807. Accessed December 12, 2013.
25. Passalacqua R, Buzio C, Buti S et al. Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC): A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol 2007; 25(suppl): LBA5028a.
26. Ryan CW, Curti BD, Quinn DI et al. A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). J Clin Oncol 2010; 28: 4528a.
27. Haas NB, Manola J, Ky B et al. Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC). J Clin Oncol 2012; 30(suppl): 4500a.
28. Cindolo L, Chiodini P, Gallo C et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2008; 113: 65-71.
29. Reinhardt C, Zdrojowy R, Szczylik C et al. Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). J Clin Oncol 2010; 28: 4529 [Meeting Abstracts].
30. Procopio G, Verzoni E, Bracarda S et al. Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010; 28: 4589a.
31. Rosenberg JE, Drabkin HA, Lara P Jr. et al. A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). J Clin Oncol 2010; 28: 4590a.
32. Dandamudi UB, Ghebremichael MS, Sosman JA et al. A phaseIIstudyof bevacizumab (B) and highdose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS). J Clin Oncol 2010; 28: 4530 [Meeting Abstracts].
33. DonskovF, JensenHK, JeppesenANetal. Interleukin-2 (IL-2)-based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008. J Clin Oncol 2010; 28: 4591a1.
34. Peña C, Lathia C, Shan M et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010; 16: 4853-4863.
35. Choueiri TK, Regan MM, Rosenberg JE et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010; 106: 772-778.
36. Belldegrun AS, Chamie K, Kloepfer P et al. ARISER: A randomized double blind phaseIIIstudyto evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trials. J Clin Oncol 2013; 31(suppl): 4507a.
37. Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial. Lancet 2008; 372: 145-154.
38. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and riskof tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 2004; 363: 594-599.
39. Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer 1996; 77: 2560-2566.
40. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-1261.
41. Figlin RA, Amin A, Dudek A et al. Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2012; 30(suppl): 348a.
42. Haas N, Lin X, Manola J et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012; 29: 761-767.
43. Richey SL, Ng C, Lim ZD et al. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011; 29: e203-e205.
44. Naito S, Kumazawa J, Omoto T et al. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: A long-term follow-up study. Int J Urol 1997; 4: 8-12.
45. Kavolius JP, Mastorakos DP, Pavlovich C et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266.
46. Amin A, Dudek A, Logan T et al. A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J Clin Oncol 2010; 28: 4588a.
47. National Comprehensive Cancer Network Clinical Practice Guidelines. Available at http: //www. nccn. org/professionals/physician_gls/f_guidelines. asp. Accessed March 29, 2010.
48. Pal SK, Kortylewski M, Yu H et al. Breaking through a plateau in renal cell carcinoma therapeutics: Development and incorporation of biomarkers. Mol Cancer Ther 2010; 9: 3115-3125.
49. Brannon AR, Reddy A, Seiler M et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010; 1: 152-163.
50. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-363.
51. KapurP, Peña-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation. Lancet Oncol 2013; 14: 159-167.
52. Gerlinger M, Albiges L. The Personalized RNA Interference to Enhance the Delivery of Individualized Cytotoxic and Targeted Therapeutics (PREDICT) approach to biomarker discovery in renal cell carcinoma. ASCO Meeting Abstracts J Clin Oncol 2011; 29(suppl): TPS179a.
53. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751-759.
54. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol 2012; 24: 207-212.
55. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
56. Drake CG, McDermott DF, Sznol M et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. J Clin Oncol 2013; 31(suppl): 4514a.
57. NCT01668784. Study of nivolumab (BMS-936558) vs. everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (CheckMate 025). Available at http: //www. clinicaltrials. gov/show/NCT01668784. Accessed December 13, 2013.
58. Cho DC, Sosman JA, Sznol M et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renalcell carcinoma (mRCC). J Clin Oncol 2013; 31(suppl): 4505a.
59. MacFarlane AW, Jillab M, Plimack ER et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2014; 2: 320-331.
60. NCT01582672. Phase 3 trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (RCC) (ADAPT). Available at http: //www. clinicaltrials. gov/show/NCT01582672. Accessed December 15, 2013.
61. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-6682.
62. NCT01265901. A randomized, controlled phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as firstline therapy for advanced/metastatic renal cell carcinoma. Available at http: //www. clinicaltrials. gov/show/NCT01265901. Accessed August 15, 2011.
63. Choueiri TK, Pal SK, McDermott DF et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol 2012; 30(suppl): 4504a.
64. Loges S, Mazzone M, Hohensinner P et al. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
65. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
66. Ebos JM, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
67. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
68. Pouliot F, Anterasian C, Klatte T et al. Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 4593a.
69. Regan MM, Neven P, Giobbie-Hurder A et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 81 years median follow-up. Lancet Oncol 2011; 12: 1101-1108.